The Experts below are selected from a list of 1794 Experts worldwide ranked by ideXlab platform
David C. Warltier - One of the best experts on this subject based on the ideXlab platform.
-
Volume Replacement Therapy during Major Orthopedic Surgery Using Voluven® (Hydroxyethyl Starch 130/0.4) or Hetastarch
Anesthesiology, 2007Co-Authors: Sweeta D. Gandhi, Richard B. Weiskopf, Cornelius Jungheinrich, Robert Koorn, Diane Miller, Robert E. Shangraw, Donald S. Prough, Daniela Baus, Frank Bepperling, David C. WarltierAbstract:Background: The purpose of this study was to test the equivalence of efficacy and compare the safety of the 6% hydroxyethyl starches (HES) Voluven® (HES 130/0.4; Fresenius Kabi, Bad Homburg, Germany) and Hetastarch (HES 670/0.75 in saline) for intravascular volume replacement therapy during major orthopedic surgery. Methods: In a prospective, controlled, randomized, double-blind, multicenter trial of patients undergoing major orthopedic surgery, 49 patients were treated with HES 130/0.4 and 51 patients were treated with Hetastarch. Infusion of colloids was guided by central venous and arterial blood pressures. The primary efficacy endpoint was the volume of colloid solution infused; the primary safety endpoints were calculated total erythrocyte loss, the nadir factor VIII activity, and the nadir von Willebrand factor concentration within 2 h of completion of surgery. Results: The total volume of colloid solution required for intraoperative volume replacement did not differ between HES 130/0.4 and Hetastarch (1,613 ± 778 [SD] ml for HES 130/0.4 and 1,584 ± 958 ml for Hetastarch). The nadir factor VIII activity within 2 h of the end of surgery was lower for Hetastarch than for HES 130/0.4 (P = 0.0499); for those who received greater than 1,000 ml colloid, the nadir factor VIII activity and von Willebrand factor concentration within 2 h of end of surgery were lower for Hetastarch than for HES 130/0.4 (P = 0.0487 and P = 0.008, respectively). Conclusion: Voluven® (HES 130/0.4) and Hetastarch are equally efficacious plasma volume substitutes; however, HES 130/0.4 has a lesser effect on coagulation.
-
volume replacement therapy during major orthopedic surgery using voluven hydroxyethyl starch 130 0 4 or Hetastarch
Anesthesiology, 2007Co-Authors: Sweeta D. Gandhi, Richard B. Weiskopf, Cornelius Jungheinrich, Robert Koorn, Diane Miller, Robert E. Shangraw, Donald S. Prough, Daniela Baus, Frank Bepperling, David C. WarltierAbstract:Background: The purpose of this study was to test the equivalence of efficacy and compare the safety of the 6% hydroxyethyl starches (HES) Voluven® (HES 130/0.4; Fresenius Kabi, Bad Homburg, Germany) and Hetastarch (HES 670/0.75 in saline) for intravascular volume replacement therapy during major orthopedic surgery. Methods: In a prospective, controlled, randomized, double-blind, multicenter trial of patients undergoing major orthopedic surgery, 49 patients were treated with HES 130/0.4 and 51 patients were treated with Hetastarch. Infusion of colloids was guided by central venous and arterial blood pressures. The primary efficacy endpoint was the volume of colloid solution infused; the primary safety endpoints were calculated total erythrocyte loss, the nadir factor VIII activity, and the nadir von Willebrand factor concentration within 2 h of completion of surgery. Results: The total volume of colloid solution required for intraoperative volume replacement did not differ between HES 130/0.4 and Hetastarch (1,613 ± 778 [SD] ml for HES 130/0.4 and 1,584 ± 958 ml for Hetastarch). The nadir factor VIII activity within 2 h of the end of surgery was lower for Hetastarch than for HES 130/0.4 (P = 0.0499); for those who received greater than 1,000 ml colloid, the nadir factor VIII activity and von Willebrand factor concentration within 2 h of end of surgery were lower for Hetastarch than for HES 130/0.4 (P = 0.0487 and P = 0.008, respectively). Conclusion: Voluven® (HES 130/0.4) and Hetastarch are equally efficacious plasma volume substitutes; however, HES 130/0.4 has a lesser effect on coagulation.
Donald S. Prough - One of the best experts on this subject based on the ideXlab platform.
-
Volume Replacement Therapy during Major Orthopedic Surgery Using Voluven® (Hydroxyethyl Starch 130/0.4) or Hetastarch
Anesthesiology, 2007Co-Authors: Sweeta D. Gandhi, Richard B. Weiskopf, Cornelius Jungheinrich, Robert Koorn, Diane Miller, Robert E. Shangraw, Donald S. Prough, Daniela Baus, Frank Bepperling, David C. WarltierAbstract:Background: The purpose of this study was to test the equivalence of efficacy and compare the safety of the 6% hydroxyethyl starches (HES) Voluven® (HES 130/0.4; Fresenius Kabi, Bad Homburg, Germany) and Hetastarch (HES 670/0.75 in saline) for intravascular volume replacement therapy during major orthopedic surgery. Methods: In a prospective, controlled, randomized, double-blind, multicenter trial of patients undergoing major orthopedic surgery, 49 patients were treated with HES 130/0.4 and 51 patients were treated with Hetastarch. Infusion of colloids was guided by central venous and arterial blood pressures. The primary efficacy endpoint was the volume of colloid solution infused; the primary safety endpoints were calculated total erythrocyte loss, the nadir factor VIII activity, and the nadir von Willebrand factor concentration within 2 h of completion of surgery. Results: The total volume of colloid solution required for intraoperative volume replacement did not differ between HES 130/0.4 and Hetastarch (1,613 ± 778 [SD] ml for HES 130/0.4 and 1,584 ± 958 ml for Hetastarch). The nadir factor VIII activity within 2 h of the end of surgery was lower for Hetastarch than for HES 130/0.4 (P = 0.0499); for those who received greater than 1,000 ml colloid, the nadir factor VIII activity and von Willebrand factor concentration within 2 h of end of surgery were lower for Hetastarch than for HES 130/0.4 (P = 0.0487 and P = 0.008, respectively). Conclusion: Voluven® (HES 130/0.4) and Hetastarch are equally efficacious plasma volume substitutes; however, HES 130/0.4 has a lesser effect on coagulation.
-
volume replacement therapy during major orthopedic surgery using voluven hydroxyethyl starch 130 0 4 or Hetastarch
Anesthesiology, 2007Co-Authors: Sweeta D. Gandhi, Richard B. Weiskopf, Cornelius Jungheinrich, Robert Koorn, Diane Miller, Robert E. Shangraw, Donald S. Prough, Daniela Baus, Frank Bepperling, David C. WarltierAbstract:Background: The purpose of this study was to test the equivalence of efficacy and compare the safety of the 6% hydroxyethyl starches (HES) Voluven® (HES 130/0.4; Fresenius Kabi, Bad Homburg, Germany) and Hetastarch (HES 670/0.75 in saline) for intravascular volume replacement therapy during major orthopedic surgery. Methods: In a prospective, controlled, randomized, double-blind, multicenter trial of patients undergoing major orthopedic surgery, 49 patients were treated with HES 130/0.4 and 51 patients were treated with Hetastarch. Infusion of colloids was guided by central venous and arterial blood pressures. The primary efficacy endpoint was the volume of colloid solution infused; the primary safety endpoints were calculated total erythrocyte loss, the nadir factor VIII activity, and the nadir von Willebrand factor concentration within 2 h of completion of surgery. Results: The total volume of colloid solution required for intraoperative volume replacement did not differ between HES 130/0.4 and Hetastarch (1,613 ± 778 [SD] ml for HES 130/0.4 and 1,584 ± 958 ml for Hetastarch). The nadir factor VIII activity within 2 h of the end of surgery was lower for Hetastarch than for HES 130/0.4 (P = 0.0499); for those who received greater than 1,000 ml colloid, the nadir factor VIII activity and von Willebrand factor concentration within 2 h of end of surgery were lower for Hetastarch than for HES 130/0.4 (P = 0.0487 and P = 0.008, respectively). Conclusion: Voluven® (HES 130/0.4) and Hetastarch are equally efficacious plasma volume substitutes; however, HES 130/0.4 has a lesser effect on coagulation.
-
Reduced cerebral blood flow, oxygen delivery, and electroencephalographic activity after traumatic brain injury and mild hemorrhage in cats.
Journal of Neurosurgery, 1992Co-Authors: Douglas S. Dewitt, Donald S. Prough, Carol L. Taylor, John M. WhitleyAbstract:✓ The authors investigated the effects of transient, mild hemorrhagic hypotension after fluid-percussion traumatic brain injury on intracranial pressure, cerebral blood flow (CBF), cerebral oxygen delivery (CBF × arterial O2 content), and electroencephalographic (EEG) activity. Adult mongrel cats were anesthetized with 1.6% isoflurane in N2O:O2 (70:30) and prepared for trauma and for radioactive microsphere CBF measurement. Isoflurane concentration was decreased to 0.8%, and the cats were randomly assigned to one of four control groups or to an experimental group. Animals in the four control groups underwent either mild hemorrhage (18 ml · kg−1) immediately followed by resuscitation with equal volumes of 10% Hetastarch (eight cats), mild hemorrhage followed by replacement of shed blood (six cats), isovolemic hemodilution with 18 ml · kg−1 of Hetastarch (six cats), or moderate (2.2 atm) trauma alone (eight cats). The experimental group received a combination of trauma and mild hemorrhage followed by resusc...
Sweeta D. Gandhi - One of the best experts on this subject based on the ideXlab platform.
-
Volume Replacement Therapy during Major Orthopedic Surgery Using Voluven® (Hydroxyethyl Starch 130/0.4) or Hetastarch
Anesthesiology, 2007Co-Authors: Sweeta D. Gandhi, Richard B. Weiskopf, Cornelius Jungheinrich, Robert Koorn, Diane Miller, Robert E. Shangraw, Donald S. Prough, Daniela Baus, Frank Bepperling, David C. WarltierAbstract:Background: The purpose of this study was to test the equivalence of efficacy and compare the safety of the 6% hydroxyethyl starches (HES) Voluven® (HES 130/0.4; Fresenius Kabi, Bad Homburg, Germany) and Hetastarch (HES 670/0.75 in saline) for intravascular volume replacement therapy during major orthopedic surgery. Methods: In a prospective, controlled, randomized, double-blind, multicenter trial of patients undergoing major orthopedic surgery, 49 patients were treated with HES 130/0.4 and 51 patients were treated with Hetastarch. Infusion of colloids was guided by central venous and arterial blood pressures. The primary efficacy endpoint was the volume of colloid solution infused; the primary safety endpoints were calculated total erythrocyte loss, the nadir factor VIII activity, and the nadir von Willebrand factor concentration within 2 h of completion of surgery. Results: The total volume of colloid solution required for intraoperative volume replacement did not differ between HES 130/0.4 and Hetastarch (1,613 ± 778 [SD] ml for HES 130/0.4 and 1,584 ± 958 ml for Hetastarch). The nadir factor VIII activity within 2 h of the end of surgery was lower for Hetastarch than for HES 130/0.4 (P = 0.0499); for those who received greater than 1,000 ml colloid, the nadir factor VIII activity and von Willebrand factor concentration within 2 h of end of surgery were lower for Hetastarch than for HES 130/0.4 (P = 0.0487 and P = 0.008, respectively). Conclusion: Voluven® (HES 130/0.4) and Hetastarch are equally efficacious plasma volume substitutes; however, HES 130/0.4 has a lesser effect on coagulation.
-
volume replacement therapy during major orthopedic surgery using voluven hydroxyethyl starch 130 0 4 or Hetastarch
Anesthesiology, 2007Co-Authors: Sweeta D. Gandhi, Richard B. Weiskopf, Cornelius Jungheinrich, Robert Koorn, Diane Miller, Robert E. Shangraw, Donald S. Prough, Daniela Baus, Frank Bepperling, David C. WarltierAbstract:Background: The purpose of this study was to test the equivalence of efficacy and compare the safety of the 6% hydroxyethyl starches (HES) Voluven® (HES 130/0.4; Fresenius Kabi, Bad Homburg, Germany) and Hetastarch (HES 670/0.75 in saline) for intravascular volume replacement therapy during major orthopedic surgery. Methods: In a prospective, controlled, randomized, double-blind, multicenter trial of patients undergoing major orthopedic surgery, 49 patients were treated with HES 130/0.4 and 51 patients were treated with Hetastarch. Infusion of colloids was guided by central venous and arterial blood pressures. The primary efficacy endpoint was the volume of colloid solution infused; the primary safety endpoints were calculated total erythrocyte loss, the nadir factor VIII activity, and the nadir von Willebrand factor concentration within 2 h of completion of surgery. Results: The total volume of colloid solution required for intraoperative volume replacement did not differ between HES 130/0.4 and Hetastarch (1,613 ± 778 [SD] ml for HES 130/0.4 and 1,584 ± 958 ml for Hetastarch). The nadir factor VIII activity within 2 h of the end of surgery was lower for Hetastarch than for HES 130/0.4 (P = 0.0499); for those who received greater than 1,000 ml colloid, the nadir factor VIII activity and von Willebrand factor concentration within 2 h of end of surgery were lower for Hetastarch than for HES 130/0.4 (P = 0.0487 and P = 0.008, respectively). Conclusion: Voluven® (HES 130/0.4) and Hetastarch are equally efficacious plasma volume substitutes; however, HES 130/0.4 has a lesser effect on coagulation.
Colin P Mcguckin - One of the best experts on this subject based on the ideXlab platform.
-
Umbilical cord blood processing using Prepacyte-CB increases haematopoietic progenitor cell availability over conventional Hetastarch separation
Cell Proliferation, 2009Co-Authors: Christina Basford, Nicolas Forraz, Saba Habibollah, Kendal Hanger, Colin P McguckinAbstract:Background: Currently the most frequently used method for umbilical cord blood separation in many hospitals across the UK and the rest of the world, where small-to-medium amounts of samples are processed, is Hetastarch, a mechanical, starch-based method, which causes red cell agglutination by rouleaux formation. Aim: In this study, a novel method (Prepa-Cyte-CB), in comparison with Hetastarch as part of an FDA-approved clinical study, was evaluated. Materials and Methods: Validation of data included recovery of nucleated and CD34+ cells, red blood cell reduction, colony forming unit potential, flow cytometric analysis and sterility tests. Results: PrepaCyte-CB, in comparison with Hetastarch offers fast, reliable separation with improved recovery of nucleated cells, 72.03% (±8.48 SD) compared to 58.09% (±20.06 SD), and CD34+ haematopoietic progenitor cells, 76% (±19.54 SD) compared to 64.19% (±29.77 SD). PrepaCyte-CB was also 12-fold more efficient in removing red blood cells and haemoglobin (P
-
Umbilical cord blood processing using Prepacyte-CB increases haematopoietic progenitor cell availability over conventional Hetastarch separation
Cell Proliferation, 2009Co-Authors: Christina Basford, Nicolas Forraz, Saba Habibollah, Kendal Hanger, Colin P McguckinAbstract:BACKGROUND: Currently the most frequently used method for umbilical cord blood separation in many hospitals across the UK and the rest of the world, where small-to-medium amounts of samples are processed, is Hetastarch, a mechanical, starch-based method, which causes red cell agglutination by rouleaux formation.\n\nAIM: In this study, a novel method (Prepa-Cyte-CB), in comparison with Hetastarch as part of an FDA-approved clinical study, was evaluated.\n\nMATERIALS AND METHODS: Validation of data included recovery of nucleated and CD34+ cells, red blood cell reduction, colony forming unit potential, flow cytometric analysis and sterility tests.\n\nRESULTS: PrepaCyte-CB, in comparison with Hetastarch offers fast, reliable separation with improved recovery of nucleated cells, 72.03% (+/-8.48 SD) compared to 58.09% (+/-20.06 SD), and CD34+ haematopoietic progenitor cells, 76% (+/-19.54 SD) compared to 64.19% (+/-29.77 SD). PrepaCyte-CB was also 12-fold more efficient in removing red blood cells and haemoglobin (P < 0.001) than Hetastarch.\n\nCONCLUSIONS: These results show that PrepaCyte-CB offers superior separation of UCB when compared to Hetastarch.
Frank Bepperling - One of the best experts on this subject based on the ideXlab platform.
-
Volume Replacement Therapy during Major Orthopedic Surgery Using Voluven® (Hydroxyethyl Starch 130/0.4) or Hetastarch
Anesthesiology, 2007Co-Authors: Sweeta D. Gandhi, Richard B. Weiskopf, Cornelius Jungheinrich, Robert Koorn, Diane Miller, Robert E. Shangraw, Donald S. Prough, Daniela Baus, Frank Bepperling, David C. WarltierAbstract:Background: The purpose of this study was to test the equivalence of efficacy and compare the safety of the 6% hydroxyethyl starches (HES) Voluven® (HES 130/0.4; Fresenius Kabi, Bad Homburg, Germany) and Hetastarch (HES 670/0.75 in saline) for intravascular volume replacement therapy during major orthopedic surgery. Methods: In a prospective, controlled, randomized, double-blind, multicenter trial of patients undergoing major orthopedic surgery, 49 patients were treated with HES 130/0.4 and 51 patients were treated with Hetastarch. Infusion of colloids was guided by central venous and arterial blood pressures. The primary efficacy endpoint was the volume of colloid solution infused; the primary safety endpoints were calculated total erythrocyte loss, the nadir factor VIII activity, and the nadir von Willebrand factor concentration within 2 h of completion of surgery. Results: The total volume of colloid solution required for intraoperative volume replacement did not differ between HES 130/0.4 and Hetastarch (1,613 ± 778 [SD] ml for HES 130/0.4 and 1,584 ± 958 ml for Hetastarch). The nadir factor VIII activity within 2 h of the end of surgery was lower for Hetastarch than for HES 130/0.4 (P = 0.0499); for those who received greater than 1,000 ml colloid, the nadir factor VIII activity and von Willebrand factor concentration within 2 h of end of surgery were lower for Hetastarch than for HES 130/0.4 (P = 0.0487 and P = 0.008, respectively). Conclusion: Voluven® (HES 130/0.4) and Hetastarch are equally efficacious plasma volume substitutes; however, HES 130/0.4 has a lesser effect on coagulation.
-
volume replacement therapy during major orthopedic surgery using voluven hydroxyethyl starch 130 0 4 or Hetastarch
Anesthesiology, 2007Co-Authors: Sweeta D. Gandhi, Richard B. Weiskopf, Cornelius Jungheinrich, Robert Koorn, Diane Miller, Robert E. Shangraw, Donald S. Prough, Daniela Baus, Frank Bepperling, David C. WarltierAbstract:Background: The purpose of this study was to test the equivalence of efficacy and compare the safety of the 6% hydroxyethyl starches (HES) Voluven® (HES 130/0.4; Fresenius Kabi, Bad Homburg, Germany) and Hetastarch (HES 670/0.75 in saline) for intravascular volume replacement therapy during major orthopedic surgery. Methods: In a prospective, controlled, randomized, double-blind, multicenter trial of patients undergoing major orthopedic surgery, 49 patients were treated with HES 130/0.4 and 51 patients were treated with Hetastarch. Infusion of colloids was guided by central venous and arterial blood pressures. The primary efficacy endpoint was the volume of colloid solution infused; the primary safety endpoints were calculated total erythrocyte loss, the nadir factor VIII activity, and the nadir von Willebrand factor concentration within 2 h of completion of surgery. Results: The total volume of colloid solution required for intraoperative volume replacement did not differ between HES 130/0.4 and Hetastarch (1,613 ± 778 [SD] ml for HES 130/0.4 and 1,584 ± 958 ml for Hetastarch). The nadir factor VIII activity within 2 h of the end of surgery was lower for Hetastarch than for HES 130/0.4 (P = 0.0499); for those who received greater than 1,000 ml colloid, the nadir factor VIII activity and von Willebrand factor concentration within 2 h of end of surgery were lower for Hetastarch than for HES 130/0.4 (P = 0.0487 and P = 0.008, respectively). Conclusion: Voluven® (HES 130/0.4) and Hetastarch are equally efficacious plasma volume substitutes; however, HES 130/0.4 has a lesser effect on coagulation.